Answers are grounded in this paper and cite their sources.
Background Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultrarare, inherited thrombotic microangiopathy caused by severe ADAMTS13 deficiency. Recombinant ADAMTS13 (rADAMTS13) provides targeted enzyme replacement, offering an alternative to plasma-based prophylaxis. Although clinical trials have demonstrated encouraging outcomes, evidence regarding long-term effectiveness and safety in routine clinical practice remains limited. This study evaluated extended hematological outcomes, acute thrombotic thrombocytopenic purpura (TTP) events, treatment continuity, and safety during rADAMTS13 prophylaxis. Methods This multicenter retrospective observational study included 10 patients with cTTP treated at 5 specialist centers in Poland. Nine patients belonged to a previously published cohort, and one additional patient was included. All had previously received fresh frozen plasma (FFP) and subsequently received intravenous rADAMTS13 at 40 IU/kg every two weeks. Clinical records and standardized physician questionnaires were reviewed through May 2026. Laboratory parameters were evaluated at pretreatment baseline, an initial on-treatment assessment, and extended follow-up. Follow-up lasted approximately 2 to 4 years in the original cohort and 11 months in the additional patient. Results All 10 patients continued regular rADAMTS13 prophylaxis without permanent treatment discontinuation or regimen modification. Mean platelet counts were 201.3 ± 93.2 × 10⁹/L at baseline, 252.0 ± 50.5 × 10⁹/L initially, and 193.1 ± 35.6 × 10⁹/L at extended follow-up. All patients had platelet counts within the reference interval at the latest assessment, compared with seven at baseline. Mean lactate dehydrogenase decreased from 239.7 ± 78.1 to 183.8 ± 25.7 U/L. Two patients (20%) experienced clinically diagnosed acute TTP episodes associated with intercurrent infections and required supplementary treatment. Incomplete event-specific laboratory documentation prevented independent verification against standardized criteria. No new strokes or clinically documented renal deterioration were reported. No ADAMTS13 inhibitors were detected in May 2026, and no serious adverse events attributed to rADAMTS13 were documented. Conclusions Extended rADAMTS13 prophylaxis was associated with favorable hematological findings at the available assessments, sustained treatment continuity, and an encouraging safety and tolerability profile. These observations provide reassuring real-world evidence supporting its potential value in the long-term management of cTTP. Nevertheless, infection-associated acute TTP events demonstrate the importance of continued clinical surveillance and timely access to additional treatment. Larger prospective studies are needed to confirm long-term effectiveness and safety.
No takes yet. Share an insight, caveat, or question.
Laguna et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: